CAPR
Capricor Therapeutics, Inc. · Healthcare · Biotechnology
Last
$27.92
+$0.03 (+0.11%) 4:00 PM ET
Prev close $27.89
Open $28.01
Day high $28.01
Day low $27.12
Volume 1,238,093
Avg vol 1,135,946
Mkt cap
$1.52B
P/E ratio
-15.95
FY Revenue
$11.13M
EPS
-1.75
Gross Margin
100.00%
Sector
Healthcare
AI report sections
CAPR
Capricor Therapeutics, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+33% (Above avg)
Vol/Avg: 1.33×
RSI
59.98 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.04 (Strong)
MACD: 0.13 Signal: 0.08
Short-Term
+0.42 (Strong)
MACD: 1.12 Signal: 0.70
Long-Term
+0.23 (Strong)
MACD: 2.19 Signal: 1.96
Intraday trend score 66.00

Latest news

CAPR 12 articles Positive: 2 Neutral: 0 Negative: 10
Positive Benzinga • Erica Kollmann
Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for its cell therapy candidate deramiocel, causing its stock to surge dramatically. Martin Shkreli, who had previously predicted the trial's failure, criticized the data and claimed the company changed its primary endpoint.

CAPR biotech clinical trial short selling Duchenne muscular dystrophy
Sentiment note

Successfully completed Phase 3 trial with strong results, stock price increased by 337.9%, CEO confident about trial outcomes

Positive Benzinga • Alex Perry
Why Capricor Therapeutics Stock Is Surging Today

Capricor Therapeutics met with the FDA to discuss regulatory approval for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA provided clarity on the approval process and showed flexibility in reviewing trial data, causing the stock to surge.

CAPR Capricor FDA Deramiocel Duchenne muscular dystrophy cell therapy
Sentiment note

Stock jumped 18% after positive FDA meeting, with regulatory pathway clarified and potential for future approval of Deramiocel therapy

Negative GlobeNewswire Inc. • The Gross Law Firm
Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR

Capricor Therapeutics received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, causing a significant stock price drop and triggering a potential securities class action lawsuit.

CAPR securities lawsuit FDA Biologics License Application stock decline deramiocel
Sentiment note

FDA denied BLA for lead drug, stock price dropped from $11.40 to $7.64, potential legal action suggests misleading investor communications about drug's effectiveness

Negative GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics alleging false and misleading statements about the safety and efficacy of its Phase 2 HOPE-2 trial for deramiocel, with potential regulatory approval challenges.

CAPR class action securities lawsuit Phase 2 trial regulatory approval investor alert
Sentiment note

The lawsuit alleges the company made materially false statements about its trial data, regulatory prospects, and business operations, suggesting potential misrepresentation and investor harm

Negative GlobeNewswire Inc. • Rosen Law Firm
CAPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm is pursuing a securities class action lawsuit against Therapeutics for allegedly providing misleading statements about its cell therapy drug deramiocel and its Phase 2 trial data, potentially causing investor damages.

CAPR securities lawsuit class action deramiocel FDA Duchenne muscular dystrophy
Sentiment note

The lawsuit alleges the company disseminated false and misleading statements about its drug's safety and efficacy data, potentially causing shareholders to purchase securities at artificially inflated prices

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit

Bragar Eagel & Squire filed a class action lawsuit against Capricor Therapeutics regarding misleading statements about its cell therapy drug deramiocel. The FDA denied the Biologics License Application, causing the stock price to drop significantly.

CAPR class action lawsuit FDA Biologics License Application stock decline
Sentiment note

FDA denied BLA for deramiocel, stock price dropped from $11.40 to $7.64, and the company is facing a class action lawsuit for allegedly providing false and misleading information to investors

Negative GlobeNewswire Inc. • Rosen Law Firm
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm alerts Capricor Therapeutics investors about a September 15, 2025 deadline for a securities class action lawsuit related to allegedly misleading statements about a cell therapy drug's safety and efficacy data.

CAPR securities class action lawsuit FDA drug trial
Sentiment note

The lawsuit alleges the company provided false and misleading statements about its drug's safety and efficacy data, potentially causing shareholders to purchase securities at artificially inflated prices

Negative GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics alleging false and misleading statements about the safety and efficacy of its Phase 2 HOPE-2 trial for deramiocel, with potential regulatory approval challenges.

CAPR class action securities lawsuit Phase 2 trial regulatory approval
Sentiment note

The lawsuit alleges the company made materially false statements about its clinical trial data, regulatory prospects, and business operations, suggesting potential misrepresentation and investor harm

Negative GlobeNewswire Inc. • Rosen Law Firm
CAPR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm alerts Capricor Therapeutics investors about a securities class action lawsuit regarding potentially misleading statements about deramiocel's safety and efficacy data during the period of October 9, 2024 to July 10, 2025.

CAPR securities class action lawsuit deramiocel FDA Biologics License Application
Sentiment note

The lawsuit alleges the company disseminated false and misleading statements about its drug's safety and efficacy data, potentially causing shareholders to purchase securities at artificially inflated prices

Negative Benzinga • Prnewswire
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics faces a class action lawsuit alleging false statements about its drug candidate's FDA approval progress, with shareholders encouraged to join a potential recovery effort.

CAPR securities lawsuit FDA approval drug candidate class action
Sentiment note

The company is accused of making false and misleading statements about its drug candidate's approval process, with allegations of hiding adverse clinical trial data, which suggests significant legal and reputational risk

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics regarding allegedly misleading statements about its cell therapy drug deramiocel, after the FDA denied its Biologics License Application and the stock price dropped significantly.

CAPR class action lawsuit FDA Biologics License Application stock decline
Sentiment note

The company received a Complete Response Letter from the FDA denying its BLA for deramiocel, citing lack of substantial evidence of effectiveness and requiring additional clinical data. This led to a significant stock price drop from $11.40 to $7.64 per share.

Negative GlobeNewswire Inc. • Faruqi & Faruqi, Llp
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi is investigating potential claims against Capricor Therapeutics after the FDA denied its Biologics License Application for deramiocel, causing the stock price to drop significantly.

CAPR securities litigation FDA class action biotechnology drug development
Sentiment note

The company received a Complete Response Letter from the FDA denying its BLA for deramiocel, which resulted in a stock price decline from $11.40 to $7.64 and triggered a potential class action lawsuit alleging false or misleading statements about the drug's effectiveness

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal